Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Discriminating active from latent tuberculosis by Mycobacterium tuberculosis (MTB)-peptide specific immunoresponses Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008
Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Hospital-based antibiotic use in patients with Mycobacterium avium complex Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018 Year: 2018
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Changes in the metabolism of Mycobacterium tuberculosis during the course of TB treatment Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis Source: Eur Respir J 2010; 35: 692-694 Year: 2010
Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017
Pulmonary tuberculosis among elderly and senile-aged patients depending on Mycobacterium strains Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
In vitro susceptibility testing of bedaquiline against mycobacteria avium-intracellulare complex Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004
Investigation of the inhibition of adherence of Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis (MTB) to the respiratory mucosa Source: Eur Respir J 2001; 18: Suppl. 33, 480s Year: 2001
Evaluation of a IFN-γ test using Mycobacterium tuberculosis -specific antigens for diagnosis of active tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 142s Year: 2006
Identification of Mycobacterium tuberculosis (MTB)-infection in immunocompromised hosts Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008